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Summary
Background An adequate amount of prepaid resources for health is important to ensure access to health services and for 
the pursuit of universal health coverage. Previous studies on global health financing have described the relationship 
between economic development and health financing. In this study, we further explore global health financing trends 
and examine how the sources of funds used, types of services purchased, and development assistance for health 
disbursed change with economic development. We also identify countries that deviate from the trends.
Methods We estimated national health spending by type of care and by source, including development assistance for 
health, based on a diverse set of data including programme reports, budget data, national estimates, and 964 National 
Health Accounts. These data represent health spending for 184 countries from 1995 through 2014. We converted 
these data into a common inflation-adjusted and purchasing power-adjusted currency, and used non-linear regression 
methods to model the relationship between health financing, time, and economic development.
Findings Between 1995 and 2014, economic development was positively associated with total health spending and a shift 
away from a reliance on development assistance and out-of-pocket (OOP) towards government spending. The largest 
absolute increase in spending was in high-income countries, which increased to purchasing power-adjusted $5221 per 
capita based on an annual growth rate of 3·0%. The largest health spending growth rates were in upper-middle-income 
(5·9) and lower-middle-income groups (5·0), which both increased spending at more than 5% per year, and spent $914 
and $267 per capita in 2014, respectively. Spending in low-income countries grew nearly as fast, at 4·6%, and health 
spending increased from $51 to $120 per capita. In 2014, 59·2% of all health spending was financed by the government, 
although in low-income and lower-middle-income countries, 29·1% and 58·0% of spending was OOP spending and 
35·7% and 3·0% of spending was development assistance. Recent growth in development assistance for health has 
been tepid; between 2010 and 2016, it grew annually at 1·8%, and reached US$37·6 billion in 2016. Nonetheless, there 
is a great deal of variation revolving around these averages. 29 countries spend at least 50% more than expected 
per capita, based on their level of economic development alone, whereas 11 countries spend less than 50% their expected 
amount.
Interpretation Health spending remains disparate, with low-income and lower-middle-income countries increasing 
spending in absolute terms the least, and relying heavily on OOP spending and development assistance. Moreover, 
tremendous variation shows that neither time nor economic development guarantee adequate prepaid health 
resources, which are vital for the pursuit of universal health coverage.
Funding The Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Substantial disparities characterise the amount of 
resources spent on health globally.1 In many low-
income countries, per capita spending remains less 
than $100 per year, and inadequate resources prevent 
people from accessing quality health care. By contrast, 
in many high-income countries, annual health 
spending has ballooned to higher than $5000 per 
capita. These divergent contexts are reflected in the 
thrust of public policy, with calls to rein in health 
spending growth in high-income countries, and appeals 
to mobilise more resources for health in low-income 
and middle-income countries.2–8
Notwithstanding these disparities, certain trends 
underpin health spending worldwide.9–11 The health 
financing transition is defined by changes in the level 
and composition of health spending. These changes are 
associated with economic development. More specifically, 
the health financing transition has two key features, 
observed across countries and across time: (1) as countries 
experience economic development, they spend more per 
capita on health; and (2) less of that spending is out-of-
pocket (OOP).12–14 It has been theorised that both features 
of the health financing transition are driven by per capita 
income growth, technological advances, maturation of 
health financing system, greater government fiscal 
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capacity, introduction of social health insurance, and 
population ageing, all associated with socioeconomic 
development. The first feature—increasing spending on 
health per capita—is important because it leads to more 
resources for health, which can lead to improved access to 
higher quality health services. The second feature—the 
declining share of health spending that is OOP—is 
important because high OOP payments can deter use of 
health-care services, which can lead to poor health 
outcomes and medical impoverishment.15–21
Changes in a country’s reliance on development 
assistance for health is also related to economic 
development. Development assistance for health tends to 
be phased out as countries develop economically, especially 
when measured as a share of total health spending. 
Eligibility criteria set by donors, such as the Global Fund 
for AIDS, Tuberculosis, and Malaria (the Global Fund), the 
World Bank’s International Development Association, and 
Gavi, the Vaccine Alliance (Gavi), are linked to gross 
national income thresholds.22 At a certain level of economic 
development, countries become ineligible to receive 
development assistance for health.
To explore the global health financing landscape and 
the patterns described by the health financing transition 
framework, this study examines spending on health in 
184 countries over a 20-year period, 1995 to 2014. These 
data capture the distinct health spending trends of low-
income, middle-income, and high-income countries. We 
track total health spending and health spending 
disaggregated by the source of the funds—spending 
originating from governments, development partners, 
OOP, and prepaid private pools, such as private insurance. 
Research in context
Evidence before this study
Understanding how national health spending in total, and 
disaggregated into government, prepaid private, out-of-pocket 
(OOP), and development assistance for health, is associated with 
economic development is important for assessing progress and 
determining fiscally appropriate financing targets. Deviation from 
these trends can be used to identify opportunities for increased 
focus and attention from development partners and domestic 
governments. Adequate health financing that is prepaid, rather 
than OOP, is crucial for the pursuit of universal health coverage.
Several studies have tracked national health spending patterns 
over time. Typically, these studies are descriptive (cross-sectional 
and time series) and focus on trends in growth in health spending 
and its determinants. A key piece of research on this topic was 
completed by Fan and Savedoff. They explored spending in 
126 countries spanning 15 years and identified key patterns in 
how growth in health spending evolves over time, especially in 
relation to per capita income. They used the term ‘‘health 
financing transition’’ to characterise two observed patterns: as 
income rises, (1) health spending per capita tends to rise, and 
(2) the share of health payments that are OOP tends to decrease.
Added value of this study
This research expands what is known about the health 
financing transition and the availability of prepaid health 
resources in three distinct ways. First, this research provides a 
more comprehensive perspective on the health financing 
patterns associated with economic development. Previously 
our research on this topic has focused on development 
assistance for health. In this research we combine these data 
with domestic spending estimates to generate a panel of data 
spanning 20 years and 184 countries. Along with development 
assistance for health, this research measures government 
health spending that is domestically generated, prepaid private 
health spending, and out-of-pocket health spending. Second, 
we use non-linear methods to assess important non-linear 
variation across time and levels of economic development. 
These trends allow us to explore how health spending from 
development partners fit with the health financing transition 
framework. This addition is crucial to explore the effect that the 
transition away from a reliance on development assistance for 
health has on health-system financing. Relative to previous 
research, this work extends the analysis to use more 
comprehensive data that focuses on the source of the health 
spending, uses robust non-linear estimation methods, and 
highlights both trends and deviations from those trends for 
184 countries. Third, we explore how the types of health-
related goods and services purchased by each country evolve 
with economic development.
Implications of all the available evidence
The findings from this study expand the understanding of the 
health financing transition. We measure health financing trends 
associated with economic development: health spending 
increases exponentially, while the share of total health spending 
that is OOP declines, especially at the highest income levels. 
The share of financing from development assistance for health, 
on average, declines before government spending becomes the 
dominant funding source, leaving a period in the transition 
where countries often rely heavily on both OOP and 
government spending. The share of spending on each type of 
goods and service is relatively stable across the development 
spectrum with substantive emergence of long-term care 
spending at the highest income levels. Despite the health 
financing trends associated with economic development, 
tremendous variation exists and suggests that neither time nor 
economic development guarantee adequate prepaid health 
resources will be available. Deviations from the health spending 
trends can identify health financing opportunities. 
Furthermore, in view of the complexity of translating growth 
into health spending, proactive steps will be needed in some 
places to mobilise adequate prepaid resources for the pursuit of 
universal health coverage.
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To highlight changes in the mix of goods and services 
purchased, health spending has also been disaggregated 
by type of goods and services purchased, such as inpatient, 
outpatient, and pharmaceutical spending. Our analyses 
focus on patterns associated with economic development 
and, importantly, highlight deviations from observed 
trends. We also assess how development assistance for 
health is disbursed globally and discuss how development 
assistance for health is a part of and affects the health 
financing transition. These data span from 1990 to 2016, 
and highlight the sources and development agencies that 
provide development assistance for health. Primary 
health focus areas and recipient regions targeted by the 
development assistance is also tracked to show who is 
receiving development assistance for health and what 
focus areas are being prioritised.
Methods
Total health spending and government, prepaid 
private, and out-of-pocket health spending
Health spending stems from four sources: the government, 
which includes general government budgets and social 
health insurance; prepaid private spending, which includes 
private insurance and non-governmental organisation 
spending; OOP payments; and development assistance for 
health. The sum of these sources make up total health-
care spending. Government, prepaid private, and OOP 
spending data were extracted from the WHO Global Health 
Observatory. These data measure the sum of all outlays for 
health maintenance, restoration, or enhancement paid for 
in cash or supplied in kind.23 This excludes indirect health 
spending, such as lost wages due to illness or transportation 
costs; spending on informal care, such as care provided by 
a family member; spending on traditional healers; and 
illegal so-called black market or under the table transactions, 
such as bribes. Spending estimates were extracted in 
national currency units and divided by gross domestic 
product (GDP), also reported in national currency units 
and reported by WHO. This fraction was multiplied by 
GDP per capita reported in inflation-adjusted 2015 PPP $.24
WHO data tracks spending by agent, such that it is 
unclear if government and prepaid private spending were 
sourced domestically. To differentiate between domestically 
and internationally financed spending, development 
assistance for health provided to the government was 
removed from WHO’s government spending estimates 
and development assistance for health provided to non-
government providers or organisations was removed from 
WHO’s prepaid private estimates.25
For the 184 countries, between 1995 and 2014, 1·7%, 
14·8%, and 1·7% of the government, prepaid private, and 
OOP health spending estimates were missing, 
respectively. These estimates were imputed in R using 
Amelia II: A program for missing data (version 1.7.4), and 
more information about these methods is provided in 
the appendix (p 19).26 The result of this approach is four 
mutually exclusive, collectively exhaustive spending 
estimates by source and time—government as source, 
prepaid private (excluding donor financing), OOP health 
spending, and development assistance for health. These 
four series were summed to form annual estimates of 
total health spending for each of the 184 countries, 
from 1995 through 2014.
Development assistance for health
Development assistance for health is the financial and in-kind 
resources transferred from development agencies to low-
income and middle-income countries with the primary 
purpose of maintaining or improving health.27 Many of the 
methods used to estimate development assistance for health 
have been used and published previously, although the input 
data and some methods have been updated and improved for 
this study.25,27,28 These estimates are based on data from all 
publicly available databases tracking development assistance, 
including project-level records from the Organisation for 
Economic Co-operation and Development (OECD) and other 
development agencies, such as the World Bank, the Global 
Fund, Gavi, and the Bill & Melinda Gates Foundation. In 
addition, audited budget statements and annual reports are 
used to estimate development assistance for health through 
2016. When disbursement data were not available, 
commitment data are adjusted to reflect disbursements. 
Disbursements are tracked comprehensively from source to 
disbursing agency, also known as the disbursing channel, to 
recipient to avoid double counting associated with 
development agencies transferring resources among 
themselves. These data are disaggregated based on the source 
of development assistance for health, disbursing channel, 
health focus area, and country recipient. Development 
assistance for health is disaggregated by health focus area—
newborn and child health, maternal health, HIV/AIDS, 
malaria, tuberculosis, non-communicable diseases, other 
infectious diseases, health system strengthening, which 
includes discretionary grants to the health sector, and other 
and unallocable—and tracks disbursements from 1990 to 
2016. Other includes projects that are for health projects that 
do not fit into any of the other health focus areas, while 
unallocable development assistance for health is that that 
does not have sufficient data to be disaggregated by health 
focus area. A more thorough presentation of these methods 
and explanation on how these methods defer from past 
research is provided in the appendix (p 41).
The Institute for Health Metrics and Evaluation’s 
(IHME) development assistance for health database 
further disaggregates funds based on whether they are 
expected to be channelled to the recipient country’s 
government, or are provided to non-governmental 
providers or organisations.29 Development assistance for 
health estimates are reported in 2015 US$, and were 
converted into 2015 purchasing-power-adjusted US$ to 
reflect the purchasing power of development assistance for 
health in the recipient country. Purchasing power parity 
exchange rates were based on data from the International 
Monetary Fund (IMF), World Bank, and WHO.
See Online for appendix
For WHO Global Health 
Observatory see http://www.
who.int/gho/en/
For the International Monetary 
Fund world economic outlook 
database see https://www. 
imf.org/external/pubs/ft/
weo/2016/02/weodata/index.aspx
For the World Bank Databank 
see http://databank.worldbank.
org/data/home.aspx
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Health spending by types of goods and services
Total health spending was also disaggregated by type of 
goods and services, such as inpatient or outpatient care. 
For this purpose, we collected all available National 
Health Account (NHA) reports. NHAs track health 
spending using an agreed upon accounting framework 
developed by the OECD, WHO, and Eurostat. The 
standards were first codified in 2001, but then updated in 
2011 to what is now known as the System of Health 
Accounts (SHA) 2011.30,31 A systematic review located, 
extracted, and published data from 872 reports 
spanning 1996 to 2010.32 We added to this review by 
searching WHO, OECD, and Eurostat databases, and 
Google for search terms “National Health Account” and 
“System of Health Account”, which identified 
178 additional NHAs. The newly collected reports are 
primarily from more recent years.
We mapped estimates based on NHA 2001 standards to 
SHA 2011 with methods described in the appendix (p 20). 
Because the NHA 2001 and SHA 2011 standards for 
tracking spending on some preventive health services 
were irreconcilable, we include only the spending on 
immunisations and early disease detection. Excluded 
categories contain spending on education and 
counselling programmes, epidemiological surveillance, 
and disaster preparedness.
Of the 1050 NHA reports identified for this research, 
only 964 NHA reports included the necessary data 
(specific information about the exclusion criterion used 
to determine the set of used NHAs outlined in the 
appendix [p 20]). These 964 reports span 108 countries 
and range from 1995 to 2014. From these, we extracted 
total and government health spending by type of goods 
and services, and aggregated spending into eight 
categories: inpatient curative and rehabilitative care; day 
and outpatient curative and rehabilitative care; long-term 
care; ancillary services; medical goods, which includes 
pharmaceuticals; governance and health-system and 
financing administration; immunisation and early 
disease detection programmes; and other care. Estimates 
by type of service were generated as a share of both total 
health spending and total government health spending. 
Other care is a residual category that includes all health 
spending not included in the other categories.
Gross domestic product data
GDP data spanning 1995 to 2015 were based on data 
collected from the International Monetary Fund, World 
Bank, the UN, the Maddison Project, and Penn World 
Tables database.33–36 These data were combined using 
regression methods and previously developed for 
producing a complete GDP time series.24 GDP data were 
reported in inflation-adjusted 2015 PPP $.
Spending by income groups and geographic regions
We report estimates aggregated by FY2016 World Bank 
income groups and Global Burden of Disease (GBD) 
super regions.37,38 World Bank income groups are four 
mutually exclusive categories assigned by the World 
Bank and based on gross national income. GBD super 
regions are seven mutually exclusive categories based on 
geography and cause of death patterns. Spending 
estimates were constructed to reflect the group or region 
as a whole. For example, the group’s health spending per 
capita is the group’s total spending divided by total 
population. Similarly, the group’s government health 
spending as a share of total spending was the group’s 
total government spending divided by the group’s total 
health spending.
Statistical analyses
We completed three primary analyses. For all three analyses, 
we used multivariate penalised spline regression to allow 
for flexible and non-linear model fit across all 184 countries 
and 20 years of data.39 First, we regressed the natural log of 
total health spending per capita on the natural log of GDP 
per capita and time. Second, we regressed four health 
spending by source fractions—development assistance for 
health and government, prepaid private, and OOP health 
spending—on GDP per capita and time. Third, we 
regressed the eight health spending by type of goods and 
services fractions—inpatient curative and rehabilitative 
care, day and outpatient curative and rehabilitative care, 
long-term care, ancillary services, medical goods, 
governance and health-system and financing admin-
istration, immunisation and early disease detection 
programmes, and other care—on GDP per capita and time. 
For the second and third analyses, the spending fractions 
(by source and by type) were each measured as a share of 
total health spending and centre log-ratio transformed, 
while GDP per capita was natural log transformed.40 To 
estimate uncertainty, the underlying data was bootstrapped 
1000 times, and all regressions were completed 
independently on each of the 1000 bootstrap samples.41,42 
Robustness checks included in the appendix (p 29) reinforce 
our qualitative conclusions, and use subsets of our data and 
also rely on the Socio-demographic Index  and the Human 
Development Index, both of which track additional 
dimensions related to socioeconomic development, rather 
than simply GDP per capita which tracks economic 
development.
To measure countries’ 2014 health spending relative to 
the expected value as determined by the fitted trend, we 
extracted the estimated country-year and year-specific 
residual (or error) from the regression analyses. The 
residuals measure the difference between the actual 2014 
spending levels and the expected 2014 spending levels 
predicted by the model relative only to the country’s GDP 
per capita. The residual measures the effect of country 
characteristics not included in the model, such as health 
burden, health-system policies, prices, and society’s 
willingness to spend on health.
In addition to this, we tested whether health spending 
per capita grew exponentially with economic 
Articles
www.thelancet.com   Vol 389   May 20, 2017 1985
development. To test these we used ordinary least 
squares to regress the natural log of health spending 
per capita on the natural log of GDP per capita. More 
details on all estimation are included in the appendix 
(p 4).
Role of the funding source
The funder of this study had no role in the study 
design, data collection, data analysis, data 
interpretation, or writing of the report. All authors had 
full access to the data in the study and JLD and CJLM 
Total health spending 
per capita ($)
Total health 
expenditure per 
GDP (%)
Domestic 
government health 
spending per total 
health spending (%)
Prepaid private 
spending per total 
health spending (%)
Out-of-pocket 
spending per total 
health spending (%)
Development 
assistance for 
health per total 
health spending (%)
Annualised rate of 
change in total health 
spending per capita, 
1995–2014 (%)
Global
Total 1279 (33 to 9237) 8·3% (1·9 to 39·3) 59·2% (0·0 to 95·5) 17·4% (0·0 to 64·8) 22·8% (2·4 to 76·6) 0·6% (0·0 to 92·3) 3·3% (–3·0 to 19·7)
Income group
High income 5221 (853 to 9237) 11·7% (2·2 to 16·6) 63·4% (42·4 to 93·9) 22·7% (0·0 to 38·8) 13·9% (2·4 to 55·7) 0·0% (0·0 to 0·1) 3·0% (–1·1 to 7·6)
Upper-middle income 914 (228 to 1980) 5·9% (2·3 to 17·2) 57·2% (19·4 to 95·5) 8·7% (0·0 to 44·2) 33·8% (4·4 to 74·2) 0·3% (0·0 to 23·2) 5·9% (–3·0 to 17·0)
Lower-middle income 267 (92 to 791) 4·3% (1·9 to 16·1) 35·9% (0·0 to 87·2) 3·1% (0·0 to 10·2) 58·0% (2·8 to 76·6) 3·0% (0·2 to 92·3) 5·0% (–1·4 to 9·4)
Low income 120 (33 to 347) 7·3% (3·6 to 39·3) 18·0% (0·0 to 48·5) 17·2% (0·0 to 64·8) 29·1% (7·8 to 54·1) 35·7% (12·9 to 92·2) 4·6% (–3·0 to 19·7)
GBD super region
Central Europe, 
eastern Europe, 
and central Asia
1364 (200 to 2845) 6·7% (2·3 to 10·3) 58·5% (19·4 to 84·8) 2·8% (0·0 to 18·9) 38·5% (11·2 to 74·2) 0·3% (0·0 to 13·7) 4·9% (1·4–9·6)
Global Burden of 
Disease high income
5460 (1322 to 9237) 12·3% (2·6 to 16·6) 62·8 %(42·4 to 93·9) 23·4% (0·0 to 38·8) 13·8% (5·3 to 55·7) 0·0% (0·0 to 0·0) 2·9% 
(–0·6 to 7·6)
Latin America 
and Caribbean
1082 (154 to 1996) 7·3% (4·3 to 11·1) 51·6% (0·0 to 95·5) 16·1% (0·0 to 29·6) 31·7% (4·4 to 64·3) 0·7% (0·0 to 40·8) 3·3% (–1·8 to 8·5)
North Africa 
and Middle East
870 (159 to 2663) 5·2% (2·2 to 9·7) 60·1% (14·3 to 91·8) 4·3% (0·0 to 14·9) 34·9% (5·9 to 76·6) 0·7% (0·0 to 30·9) 4·9% (–1·4 to 9·0)
South Asia 223 (92 to 279) 4·2% (2·7 to 5·8) 31·0% (22·7 to 70·7) 2·6% (0·0 to 6·1) 64·7% (25·1 to 65·6) 1·7% (0·7 to 17·8) 5·8% (2·0 to 6·4)
Southeast Asia, 
east Asia, and Oceania
588 (105 to 1980) 4·8% (1·9 to 17·2) 58·6% (0·0 to 93·6) 5·2% (0·0 to 10·2) 35·7% (2·4 to 65·4) 0·5% (0·0 to 92·3) 8·9% (–3·0 to 11·0)
Sub-Saharan Africa 218 (33 to 1411) 5·9% (3·0 to 39·3) 33·5% (0·0 to 80·7) 20·8% (0·0 to 64·8) 29·2% (5·1 to 70·1) 16·6% (0·1 to 92·2) 3·2% (–3·0 to 19·7)
Country
Afghanistan 159 9·7% 15·0% 0·0% 54·1% 30·9% 5·5%
Albania 642 5·9% 48·3% 0·0% 49·8% 1·9% 4·2%
Algeria 1004 7·2% 72·7% 0·7% 26·5% 0·0% 6·0%
Andorra 5723 8·1% 78·0% 6·0% 15·9% 0·0% 2·5%
Angola 228 3·0% 70·0% 0·0% 26·6% 3·4% 1·5%%
Antigua and Barbuda 1213 5·5% 68·3% 8·0% 23·7% 0·0% 3·0%
Argentina 1322 4·8% 55·8% 13·2% 30·9% 0·0% –0·6%
Armenia 395 4·5% 40·6% 3·0% 52·8% 3·6% 4·9%
Australia 4032 9·0% 70·4% 9·9% 19·7% 0·0% 3·3%
Austria 5471 11·2% 78·0% 5·8% 16·2% 0·0% 2·6%
Azerbaijan 1030 5·9% 20·9% 4·3% 74·2% 0·6% 9·6%
Bahrain 2258 4·8% 65·3% 10·6% 24·1% 0·0% 2·2%
Bangladesh 92 2·9% 22·7% 0·0% 65·6% 11·7% 3·2%
Barbados 1116 7·5% 63·5% 6·6% 29·9% 0·0% 2·0%
Belarus 1093 5·6% 66·9% 0·1% 32·6% 0·4% 4·0%
Belgium 4751 10·6% 77·9% 4·3% 17·8% 0·0% 3·3%
Belize 503 5·8% 64·7% 9·5% 23·0% 2·9% 2·8%
Benin 105 5·1% 35·0% 0·0% 35·5% 29·6% 2·0%
Bhutan 279 3·6% 70·7% 0·0% 25·1% 4·2% 4·0%
Bolivia 404 6·3% 70·2% 3·4% 23·1% 3·3% 5·2%
Bosnia and 
Herzegovina
992 9·5% 70·0% 0·0% 28·0% 2·0% 8·8%
Botswana 903 5·5% 49·9% 35·0% 5·1% 10·0% 5·1%
Brazil 1357 8·3% 45·9% 28·5% 25·5% 0·1% 3·3%
(Table 1 continues on next page)
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Total health spending 
per capita ($)
Total health 
expenditure per 
gross domestic 
product (%)
Domestic 
government health 
spending per total 
health spending (%)
Prepaid private 
spending per total 
health spending (%)
Out-of-pocket 
spending per total 
health spending (%)
Development 
assistance for 
health per total 
health spending (%)
Annualised rate of 
change in total health 
spending per capita, 
1995–2014 (%)
(Continued from the previous page)
Brunei 1811 2·6% 93·9% 0·1% 6·0% 0·0% –0·4%
Bulgaria 1490 8·4% 54·7% 0·9% 44·3% 0·2% 6·3%
Burkina Faso 83 5·0% 35·8% 0·0% 38·6% 25·6% 2·8%
Burundi 65 8·3% 23·7% 0·0% 19·1% 57·2% 3·2%
Cambodia 209 6·4% 14·2% 0·0% 65·4% 20·4% 4·1%
Cameroon 116 4·0% 17·0% 3·5% 68·5% 10·9% 1·3%
Canada 4576 10·3% 72·1% 14·1% 13·8% 0·0% 2·4%
Cape Verde 318 4·8% 58·4% 0·1% 22·2% 19·2% 4·1%
Central African 
Republic
35 5·7% 9·0% 0·0% 34·2% 56·7% –1·3%
Chad 89 3·8% 48·5% 1·3% 37·2% 12·9% 0·6%
Chile 1780 7·8% 49·5% 19·0% 31·5% 0·0% 4·1%
China 697 5·1% 60·3% 5·0% 34·6% 0·0% 10·4%
Colombia 975 7·2% 71·9% 9·5% 15·3% 3·2% 2·7%
Comoros 111 7·1% 22·1% 20·1% 42·8% 14·9% –1·2%
Costa Rica 1418 9·3% 73·1% 1·8% 25·0% 0·0% 4·6%
Côte d’Ivoire 179 5·3% 22·1% 8·2% 54·6% 15·1% 0·2%
Croatia 1734 7·8% 81·9% 6·9% 11·2% 0·0% 3·5%
Cuba 1706 11·1% 95·5% 0·0% 4·4% 0·2% 8·5%
Cyprus 2019 7·2% 46·0% 4·4% 49·6% 0·0% 3·0%
Czech Republic 2384 7·4% 84·8% 0·8% 14·4% 0·0% 2·8%
DR Congo 46 4·5% 21·3% 0·0% 37·4% 41·3% 2·9%
Denmark 5075 10·8% 84·8% 1·9% 13·4% 0·0% 2·8%
Djibouti 357 10·9% 58·3% 0·0% 34·6% 7·1% 5·3%
Dominica 599 5·5% 68·7% 3·0% 28·3% 0·0% 1·1%
Dominican Republic 601 4·4% 63·4% 11·4% 21·0% 4·2% 3·0%
Ecuador 1071 9·2% 48·8% 2·2% 48·5% 0·5% 8·0%
Egypt 581 5·4% 39·9% 1·5% 58·3% 0·2% 5·5%
El Salvador 567 6·8% 64·7% 4·9% 28·8% 1·6% 3·3%
Equatorial Guinea 1411 3·7% 79·2% 0·0% 20·7% 0·1% 17·0%
Eritrea 59 5·1% 23·4% 0·0% 35·2% 41·4% –1·1%
Estonia 1830 6·4% 79·0% 0·3% 20·8% 0·0% 5·1%
Ethiopia 85 5·5% 26·9% 0·0% 28·4% 44·7% 7·6%
Federated States 
of Micronesia
490 16·1% 0·0% 0·0% 7·7% 92·3% 2·9%
Fiji 399 4·5% 63·8% 7·5% 23·0% 5·7% 3·3%
Finland 3935 9·3% 78·0% 3·1% 18·9% 0·0% 3·1%
France 4589 11·3% 79·9% 13·6% 6·5% 0·0% 2·0%
Gabon 612 3·4% 67·4% 8·8% 22·0% 1·8% 0·0%
Georgia 700 7·3% 19·4% 18·9% 59·1% 2·6% 9·3%
Germany 5356 11·2% 77·3% 9·4% 13·3% 0·0% 2·6%
Ghana 146 3·5% 52·8% 3·1% 27·1% 17·0% 4·3%
Greece 2170 8·1% 61·7% 3·4% 34·9% 0·0% 0·9%
Grenada 737 6·1% 46·6% 2·0% 51·2% 0·2% 2·0%
Guatemala 466 6·2% 36·9% 8·2% 52·1% 2·8% 3·9%
Guinea 101 7·4% 20·4% 0·0% 34·5% 45·1% 3·5%
Guinea-Bissau 77 5·3% 6·0% 0·0% 52·1% 41·9% –3·0%
Guyana 438 5·4% 53·5% 2·9% 36·5% 7·1% 3·2%
Haiti 154 8·9% 0·0% 29·6% 29·6% 40·8% –1·8%
(Table 1 continues on next page)
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Honduras 420 8·8% 47·2% 5·0% 43·3% 4·6% 4·4%
Hungary 1855 7·2% 68·1% 4·4% 27·5% 0·0% 2·5%
Iceland 3959 8·7% 82·3% 0·0% 17·7% 0·0% 2·3%
India 253 4·5% 31·3% 2·4% 65·6% 0·7% 6·4%
Indonesia 265 2·5% 42·7% 2·7% 53·5% 1·1% 5·2%
Iran 1073 6·5% 43·8% 5·3% 50·8% 0·0% 6·2%
Iraq 828 5·7% 58·2% 3·0% 38·4% 0·5% 7·5%
Ireland 4006 7·6% 67·6% 14·3% 18·1% 0·0% 4·6%
Israel 2722 7·7% 61·5% 11·2% 27·3% 0·0% 1·9%
Italy 3311 9·0% 77·4% 0·9% 21·7% 0·0% 1·8%
Jamaica 477 5·4% 50·5% 19·4% 27·8% 2·3% 1·7%
Japan 3816 10·2% 83·6% 2·4% 13·9% 0·0% 3·0%
Jordan 839 7·4% 66·8% 8·0% 21·1% 4·1% 2·7%
Kazakhstan 1143 4·3% 54·4% 0·0% 45·3% 0·3% 5·8%
Kenya 197 6·4% 37·8% 3·8% 23·4% 35·0% 3·4%
Kiribati 168 9·6% 79·3% 0·0% 2·8% 17·9% 0·3%
Kuwait 2075 3·0% 85·9% 1·3% 12·7% 0·0% –1·1%
Kyrgyzstan 236 6·9% 47·7% 1·3% 37·3% 13·7% 3·1%
Laos 113 2·0% 28·3% 0·4% 36·6% 34·7% 1·8%
Latvia 1427 5·9% 63·2% 1·7% 35·1% 0·0% 5·5%
Lebanon 1060 6·4% 47·6% 14·9% 36·4% 1·1% –1·2%
Lesotho 319 11·6% 63·4% 0·3% 15·0% 21·3% 6·1%
Liberia 345 39·3% 0·0% 0·0% 7·8% 92·2% 19·7%
Libya 751 5·0% 73·5% 0·0% 26·5% 0·0% 0·0%
Lithuania 1830 6·5% 67·9% 0·8% 31·3% 0·0% 7·2%
Luxembourg 7105 6·9% 83·9% 5·5% 10·6% 0·0% 3·2%
Macedonia 887 6·5% 63·1% 0·0% 36·6% 0·3% 1·4%
Madagascar 52 3·7% 29·5% 0·0% 34·3% 36·2% –0·4%
Malawi 148 12·9% 33·5% 14·0% 9·3% 43·1% 5·5%
Malaysia 1047 4·1% 56·0% 8·1% 35·8% 0·0% 5·1%
Maldives 1980 13·5% 79·4% 2·0% 18·5% 0·0% 11·0%
Mali 162 7·4% 22·0% 10·9% 43·6% 23·5% 4·0%
Malta 3058 9·7% 69·2% 2·0% 28·9% 0·0% 5·5%
Marshall Islands 599 17·2% 62·9% 2·1% 11·8% 23·2% –3·0%
Mauritania 153 3·7% 44·5% 1·4% 44·7% 9·3% 0·7%
Mauritius 880 4·6% 50·8% 0·7% 48·0% 0·4% 4·8%
Mexico 1088 6·3% 51·7% 4·2% 44·0% 0·1% 2·9%
Moldova 527 10·3% 47·2% 8·2% 38·3% 6·3% 3·4%
Mongolia 575 4·7% 51·4% 0·9% 41·9% 5·8% 8·4%
Montenegro 1015 6·6% 55·3% 2·7% 41·4% 0·6% 3·4%
Morocco 505 5·9% 33·1% 7·6% 58·4% 0·9% 5·6%
Mozambique 92 7·8% 10·6% 0·6% 8·5% 80·2% 7·4%
Myanmar 121 2·5% 36·2% 0·0% 45·6% 18·2% 9·4%
Namibia 936 9·3% 53·5% 31·2% 6·9% 8·4% 5·2%
Nepal 138 5·8% 28·6% 5·9% 47·7% 17·8% 3·1%
Netherlands 5234 10·7% 88·4% 6·3% 5·3% 0·0% 3·9%
New Zealand 4050 11·0% 82·3% 6·6% 11·0% 0·0% 4·2%
Nicaragua 450 9·1% 50·9% 3·8% 37·3% 8·0% 3·6%
(Table 1 continues on next page)
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Niger 66 6·7% 26·3% 0·0% 49·5% 24·2% 0·6%
Nigeria 225 3·7% 22·1% 0·8% 70·1% 7·0% 7·5%
Norway 6537 10·0% 83·1% 3·7% 13·2% 0·0% 3·3%
Oman 1467 3·5% 91·8% 2·3% 5·9% 0·0% 1·6%
Pakistan 132 2·7% 32·1% 6·1% 55·4% 6·4% 2·0%
Panama 1743 8·0% 72·5% 4·5% 22·3% 0·8% 4·8%
Papua New Guinea 108 4·4% 60·1% 3·9% 10·1% 25·9% 3·5%
Paraguay 863 9·8% 45·6% 4·6% 49·3% 0·5% 4·7%
Peru 626 5·2% 63·3% 6·3% 30·0% 0·4% 4·4%
Philippines 330 4·7% 33·6% 10·2% 54·3% 1·9% 4·4%
Poland 1629 6·3% 71·4% 5·0% 23·6% 0·0% 5·0%
Portugal 2697 9·3% 66·6% 5·9% 27·6% 0·0% 3·3%
Qatar 2663 2·2% 85·7% 7·4% 6·9% 0·0% 0·7%
Congo (Brazzaville) 312 5·2% 80·7% 0·3% 17·4% 1·7% 4·5%
Romania 1077 5·5% 79·1% 0·4% 18·9% 1·6% 7·2%
Russia 1877 7·1% 51·8% 2·8% 45·5% 0·0% 5·4%
Rwanda 158 9·4% 0·0% 22·4% 22·6% 55·0% 7·9%
Saint Lucia 755 6·7% 49·2% 0·8% 45·6% 4·4% 1·4%
Saint Vincent 
and the Grenadines
917 8·8% 46·1% 2·0% 48·2% 3·6% 3·4%
Samoa 365 7·2% 87·2% 0·0% 5·9% 6·9% 4·5%
São Tomé and 
Príncipe
251 7·9% 31·1% 8·0% 11·9% 49·0% 1·9%
Saudi Arabia 2320 4·4% 78·7% 6·2% 15·1% 0·0% 5·0%
Senegal 121 5·2% 39·4% 0·0% 33·8% 26·9% 2·1%
Serbia 1392 10·3% 62·5% 0·3% 37·0% 0·1% 6·9%
Seychelles 853 3·3% 93·6% 4·0% 2·4% 0·1% –0·2%
Sierra Leone 255 13·5% 5·1% 9·2% 50·1% 35·6% 3·0%
Singapore 3981 4·8% 42·4% 1·9% 55·7% 0·0% 6·5%
Slovakia 2203 7·7% 76·3% 0·0% 23·7% 0·0% 5·1%
Slovenia 2845 9·1% 73·2% 14·5% 12·3% 0·0% 3·5%
Solomon Islands 107 5·8% 67·0% 0·0% 4·0% 29·1% 2·7%
Somalia 33 6·9% 25·0% 1·2% 28·5% 45·2% 1·9%
South Africa 1172 8·9% 47·0% 44·2% 6·4% 2·4% 2·1%
South Korea 2507 7·1% 56·0% 6·6% 37·4% 0·0% 7·6%
South Sudan 94 3·6% 21·0% 0·0% 40·7% 38·3% 1·8%
Spain 3096 9·0% 71·1% 4·8% 24·1% 0·0% 2·6%
Sri Lanka 402 3·5% 54·5% 1·0% 42·3% 2·1% 5·2%
Sudan 334 8·3% 20·4% 0·9% 76·6% 2·2% 9·0%
Suriname 731 4·3% 67·6% 15·5% 15·2% 1·7% 2·0%
Swaziland 745 9·5% 66·6% 8·4% 10·0% 15·0% 4·7%
Sweden 5446 11·8% 85·1% 0·6% 14·2% 0·0% 4·0%
Switzerland 7831 12·8% 60·3% 15·2% 24·5% 0·0% 3·2%
Syria 562 3·4% 44·5% 3·3% 51·6% 0·6% –1·4%
Tajikistan 200 7·3% 22·9% 8·7% 57·9% 10·6% 7·3%
Tanzania 166 6·4% 20·3% 17·1% 20·2% 42·4% 7·2%
Thailand 633 4·1% 78·7% 8·6% 12·1% 0·7% 3·7%
The Bahamas 1996 7·7% 45·9% 24·9% 29·2% 0·0% 1·2%
The Gambia 151 9·2% 47·4% 0·0% 13·6% 39·0% 5·8%
(Table 1 continues on next page)
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Results
Health spending in 2014
Table 1 shows that in 2014 health spending per capita 
across all countries was $1279. This spending was 
concentrated in high-income countries, and ranged 
from $33 in Somalia to $9237 in the USA. These 
extremes, which are reported using 2015 PPP $ to 
account for inflation and different prices across 
countries, highlight the tremendous variation in how 
much is spent on health around the world. Disparate 
spending levels also exist within World Bank income 
groups. In 2014, health spending across low-income 
countries was $120 per capita, but range from $33 
(Somalia) to $347 (Uganda). Spending per capita across 
lower-middle-income countries was $267, but ranged 
from $92 (Bangladesh) to $791 (Tunisia), while 
spending per capita in upper-middle-income countries 
was $914, but ranged from $228 (Angola) to $1980 
(Maldives). Finally, health spending per capita 
was $5221 in high-income countries, and ranged 
from $853 (Seychelles) to $9237 (USA). Geographic 
variation is also present when examined using GBD 
super regions.
Table 1 also highlights the sources of health financing 
in 2014. Globally, governments provided 59·2% of health 
spending, while 17·4% of total health financing was 
prepaid private, 22·8% was OOP, and 0·6% was 
development assistance for health. In low-income 
countries, health spending was predominately financed 
by development assistance for health and OOP, 
constituting 35·7% and 29·1% of total health spending, 
respectively. However, the share of health financing 
sourced from OOP is largest in lower-middle-income 
countries, at 58·0%, where development assistance for 
health makes up a smaller share of total health spending 
than in low-income countries. Governments in upper-
middle-income and high-income countries, by contrast, 
finance the bulk of health care and related activities, at 
57·2% and 63·4%, respectively. Across all income 
groups, prepaid private health spending remained quite 
low. Within income groups, and also GBD super regions, 
the composition of sources financing the health system 
varied dramatically.
Health spending trends across time
Figure 1 highlights how total health spending per 
capita has changed between 1995 and 2014. Upper-
middle and lower-middle-income country groups have 
increased per capita health spending the fastest, with 
annualised growth rates of 5·9% and 5·0%, 
respectively. Over the course of 20 years, this has led to 
a near tripling of health spending per capita in upper-
middle-income countries, from $309 to $914 per capita. 
Total health spending 
per capita ($)
Total health 
expenditure per 
gross domestic 
product (%)
Domestic 
government health 
spending per total 
health spending (%)
Prepaid private 
spending per total 
health spending (%)
Out-of-pocket 
spending per total 
health spending (%)
Development 
assistance for 
health per total 
health spending (%)
Annualised rate of 
change in total health 
spending per capita, 
1995–2014 (%)
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Timor-Leste 105 1·9% 51·6% 0·0% 7·4% 41·0% 8·3%
Togo 81 5·5% 29·7% 7·8% 44·3% 18·3% 1·9%
Tonga 253 5·3% 69·5% 0·4% 11·7% 18·5% 1·7%
Trinidad and Tobago 1823 5·8% 54·5% 6·8% 38·7% 0·0% 6·2%
Tunisia 791 6·9% 57·2% 4·5% 38·1% 0·2% 3·5%
Turkey 1040 5·3% 78·4% 3·5% 18·0% 0·1% 6·6%
Turkmenistan 396 2·3% 59·2% 8·7% 31·6% 0·6% 5·3%
Uganda 347 18·1% 0·9% 64·8% 16·4% 18·0% 9·3%
Ukraine 659 7·0% 51·3% 0·9% 46·8% 0·9% 2·9%
United Arab Emirates 2561 3·6% 72·3% 9·9% 17·8% 0·0% –0·4%
UK 3749 9·1% 83·1% 7·1% 9·7% 0·0% 3·4%
USA 9237 16·6% 49·8% 38·8% 11·4% 0·0% 2·9%
Uruguay 1837 8·6% 71·2% 13·2% 15·6% 0·0% 2·9%
Uzbekistan 397 5·9% 51·9% 2·6% 43·7% 1·7% 3·6%
Vanuatu 149 5·4% 56·7% 0·0% 5·4% 37·9% 4·1%
Venezuela 1010 5·3% 29·3% 6·3% 64·3% 0·0% 1·0%
Vietnam 398 7·0% 53·0% 6·9% 37·4% 2·7% 7·0%
Yemen 233 5·8% 14·3% 1·7% 74·7% 9·3% 3·0%
Zambia 216 5·4% 32·6% 0·0% 27·7% 39·7% 4·8%
Data in parenthesis are range within aggregate. Currency are 2015 purchasing power parity US$. GBD=Global Burden of Disease.
Table 1: Health spending by source, 2014
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Spending in low-income countries grew at 4·6%, while 
the slowest growth was observed in high-income 
countries, which grew collectively at 3·0% per year. 
Despite this slower rate, the largest health spending 
increases in terms of dollar per capita increase was in 
high-income countries, which added $2244 per capita 
in spending. Upper-income and lower-income 
countries added $605 and $162 per capita respectively. 
Low-income countries, which spent very little in 1995, 
increased health spending by $69 per capita between 
1995 and 2014. Liberia, Equatorial Guinea, and 
Maldives had the fastest per capita growth rates 
between 1995 and 2014 (table 1).
For high-income and middle-income countries, the 
growth in spending was driven by increases in government 
spending. For example, in high-income countries, 
64·5% of the $2244 increase was due to increases in 
government spending. Conversely, the growth in low-
income countries was driven by increases in development 
assistance for health (51·0% of absolute increase).
Although we observed increases in spending per capita 
between 1995 and 2014 in 170 of 184 countries, the 
multivariate penalised spline analysis shows that when 
controlling on GDP per capita, there was essentially no 
change in health spending across time at the median 
health spending per capita value (appendix p 36 illustrates 
this null finding).
Health spending trends and economic development
Although time does not seem to be associated with health 
spending per capita, our trend analyses confirm the 
relationship between economic development and health 
financing—total health spending increases with 
economic development, while the share of OOP 
financing decreases. These associations are represented 
in figure 2. Across countries, growth in GDP per capita 
was associated with exponential growth in total health 
spending per capita (figure 2A; appendix p 40; p<0·000).
Figure 2B shows that when measured as a share of 
GDP, there is not a robust relationship connecting 
economic development and spending. The estimated fit 
is nearly flat and there are countries with similar GDP 
per capita with disparate spending levels.
Figure 2C and 2D show that the share of health 
spending from the government increases with economic 
development, while the share that is OOP decreases. 
Prepaid private spending as a share of total spending is 
very small, on average, across all levels of economic 
development (figure 2E), while the share of health 
spending that is development assistance for health 
increases at the very lowest levels of GDP per capita and 
peaks at GDP per capita of $801 (figure 2F).
Figure 3 shows how the fraction of total health 
spending from governments, prepaid private, OOP, and 
development assistance for health evolve, on average, 
with economic development. On average, the proportion 
of total health spending sourced from governments rise 
as GDP per capita increases. At the 80th wealth percentile 
(GDP per capita of $27 617), trend analysis estimates that 
health spending is financed by the governments (72·2%), 
with only 24·9% sourced from OOP. At the 20th wealth 
percentile (GDP per capita of $2267), trend analysis 
estimates that OOP financing is 44·8% of total spending, 
while development assistance for health is 23·1%.
Sub-Saharan Africa
South Asia
Southeast Asia, east Asia, and Oceania
North Africa and Middle East
Latin America and Caribbean
Central Europe, eastern Europe, and central Asia
Global Burden of Disease high income
GBD super region
Lower income
Lower-middle income
Upper-middle income
High-income
World Bank income group
0 2 4 6 8 10
Annualised rate of change in total health spending per capita, 1995–2014 (%)
0 2400200016001200800400
Change in total health spending per capita, 1995–2014 ($)
Change in total health spending 
per capita
Annualised rate of change in total 
health spending per capita
Figure 1: Changes in health spending by income group and Global Burden of Disease (GBD) super region, 1995–2014
Currency reported in 2015 purchasing power parity adjusted $.
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Deviation from the health financing trends
Table 2 measures health spending relative to the 
modelled amount, which is based on country-specific 
and year-specific GDP per capita. The first column 
reports total health spending for 2014, which, as figure 2A 
shows, increases exponentially with GDP per capita. 
Countries such as Afghanistan, Brazil, France, Liberia, 
Uganda, and the USA spent more in 2014 than the 
modelled average, based on each country’s GDP per 
capita. On the other hand, countries such as Timor-Leste, 
Laos, and Turkmenistan spend 33·0%, 34·7%, and 35·6% 
of the expected amount.
Columns 2 to 5 of table 2 report the share of health 
spending financed by different sources relative to the 
expected amount. The results show that some countries 
deviate substantially from average trends. For 
government health spending, Rwanda, Liberia, and 
Federated States of Micronesia stand out as countries 
that finance a smaller share than expected relative to 
respective GDP per capita. On the other hand, Kiribati, 
Solomon Islands, and The Gambia have governments 
that finance a greater share than expected. By contrast 
with the government health financing share, the OOP 
share of total health spending declines with economic 
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Figure 2: Health spending by source (total health spending [A, B], government health spending [C]; out-of-pocket health spending [D]; prepaid private 
health spending [E], and development assistance for health [F]), 2014
Health spending relative to gross domestic product (GDP) per capita (reported in 2015 purchasing-power-parity [PPP] adjusted $). Although all countries and years of 
data were used for this analysis, the trend line reflects the 2014 model fit.
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Figure 3: Composition of health-care spending by source, 2014
PPP=purchasing-power-parity.
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Total health 
spending relative 
to modelled total 
health spending (%)
Share of total health 
spending that is from 
the government, 
relative to the 
modelled share (%)
Share of total health 
spending that is 
prepaid private, 
relative to the 
modelled share (%)
Share of total health 
spending that is out-of-
pocket, relative to the 
modelled share (%)
Share of total health 
spending that is 
development assistance, 
relative to the modelled 
share (%)
Afghanistan 153·8% 64·0% 0·3% 123·7% 96·3%
Albania 99·5% 78·6% 0·6% 141·5% 170·3%
Algeria 118·0% 113·8% 30·3% 80·0% 8·8%
Andorra 141·7% 99·6% 167·6% 88·2% 0·0%
Angola 52·0% 122·2% 0·0% 70·3% 109·7%
Antigua and Barbuda 81·1% 98·7% 293·5% 84·8% 9·6%
Argentina 65·2% 77·2% 475·9% 124·3% 30·8%
Armenia 78·7% 69·0% 158·5% 142·9% 162·4%
Australia 121·3% 91·4% 333·2% 98·6% 0·0%
Austria 154·6% 100·6% 191·4% 83·2% 0·0%
Azerbaijan 91·3% 31·4% 164·4% 242·1% 263·9%
Bahrain 66·0% 84·5% 354·1% 121·9% 0·0%
Bangladesh 49·2% 56·7% 0·0% 149·9% 76·7%
Barbados 120·6% 98·2% 264·0% 92·2% 0·0%
Belarus 84·3% 98·7% 5·5% 111·0% 232·0%
Belgium 142·9% 101·2% 144·0% 88·9% 0·0%
Belize 100·1% 109·7% 498·3% 62·2% 131·1%
Benin 82·8% 120·8% 0·0% 79·3% 115·9%
Bhutan 62·9% 123·3% 0·0% 66·3% 137·8%
Bolivia 110·7% 128·8% 225·1% 59·0% 68·2%
Bosnia and Herzegovina 162·4% 114·9% 0·0% 78·6% 154·6%
Botswana 86·4% 75·9% 1352·6% 16·4% 3595·7%
Brazil 131·4% 70·0% 1104·9% 81·0% 33·1%
Brunei 45·0% 119·9% 2·8% 33·1% 0·0%
Bulgaria 130·6% 82·1% 33·2% 145·0% 72·0%
Burkina Faso 80·1% 152·7% 0·0% 88·2% 80·0%
Burundi 119·3% 161·9% 0·0% 49·3% 124·5%
Cambodia 109·2% 35·0% 0·0% 149·9% 137·0%
Cameroon 67·3% 45·1% 404·5% 155·1% 63·6%
Canada 138·7% 93·8% 475·0% 68·8% 0·0%
Cape Verde 83·0% 105·6% 9·4% 57·3% 446·0%
Central African Republic 77·4% 59·1% 0·0% 88·4% 125·3%
Chad 63·1% 151·3% 168·8% 83·1% 57·9%
Chile 111·6% 70·8% 693·3% 115·4% 3·3%
China 83·9% 94·7% 208·7% 103·9% 5·9%
Colombia 118·8% 113·1% 394·1% 46·0% 586·2%
Comoros 111·9% 99·1% 2797·1% 98·6% 44·5%
Congo 90·7% 150·8% 17·6% 44·0% 31·0%
Costa Rica 147·8% 112·5% 71·1% 78·0% 8·3%
Côte d’Ivoire 90·7% 53·6% 869·3% 125·5% 105·6%
Croatia 113·0% 117·9% 253·3% 40·5% 0·0%
Cuba 177·8% 146·9% 0·0% 13·7% 44·9%
Cyprus 98·4% 63·6% 157·4% 200·1% 0·0%
Czech Republic 98·4% 114·6% 28·1% 62·2% 0·0%
Congo (Brazzaville) 66·9% 134·1% 0·0% 93·5% 95·1%
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Denmark 147·3% 109·7% 62·3% 67·9% 0·0%
Djibouti 186·7% 143·9% 0·0% 79·4% 47·5%
Dominica 92·9% 111·7% 135·8% 80·5% 3·5%
Dominican Republic 72·4% 99·4% 472·1% 63·1% 789·2%
Ecuador 153·4% 78·5% 96·8% 139·9% 59·0%
Egypt 91·0% 65·1% 68·6% 165·3% 20·8%
El Salvador 117·8% 110·7% 262·7% 77·3% 66·3%
Equatorial Guinea 48·7% 104·6% 0·0% 96·9% 480·8%
Eritrea 78·2% 136·8% 0·0% 86·0% 100·3%
Estonia 86·0% 108·6% 9·6% 85·0% 0·0%
Ethiopia 87·6% 122·7% 0·0% 65·6% 131·3%
Federated States 
of Micronesia
273·0% 0·0% 0·0% 17·5% 566·3%
Fiji 77·8% 107·8% 390·3% 62·4% 277·3%
Finland 124·2% 101·9% 105·6% 92·2% 0·0%
France 150·0% 104·9% 467·6% 31·1% 0·0%
Gabon 52·9% 101·1% 332·0% 72·4% 853·0%
Georgia 126·5% 32·3% 941·1% 162·8% 151·8%
Germany 154·4% 100·0% 311·0% 67·6% 0·0%
Ghana 61·0% 114·5% 286·3% 64·4% 159·6%
Greece 111·0% 85·8% 124·1% 138·0% 0·0%
Grenada 102·0% 74·5% 88·4% 148·8% 27·3%
Guatemala 108·6% 64·7% 477·2% 137·2% 85·3%
Guinea 115·4% 103·8% 0·0% 81·5% 120·9%
Guinea-Bissau 83·7% 29·2% 0·0% 121·8% 116·5%
Guyana 92·9% 92·0% 155·8% 97·7% 275·7%
Haiti 142·4% 0·0% 4032·0% 67·1% 133·3%
Honduras 153·3% 96·0% 413·0% 105·1% 54·1%
Hungary 99·8% 95·4% 159·5% 106·5% 0·0%
Iceland 118·2% 106·8% 0·0% 88·9% 0·0%
India 77·6% 59·5% 175·1% 164·5% 10·8%
Indonesia 42·5% 69·8% 124·6% 151·0% 93·9%
Iran 102·6% 66·6% 204·4% 162·2% 15·6%
Iraq 92·8% 90·4% 121·4% 117·3% 105·0%
Ireland 108·8% 86·9% 457·8% 94·9% 0·0%
Israel 101·9% 82·1% 393·6% 123·1% 0·0%
Italy 119·0% 102·7% 32·4% 99·7% 0·0%
Jamaica 92·9% 85·4% 1005·4% 75·5% 112·7%
Japan 134·4% 110·7% 84·7% 64·6% 0·0%
Jordan 124·4% 107·9% 358·9% 60·6% 422·4%
Kazakhstan 60·0% 75·9% 1·2% 177·3% 649·7%
Kenya 108·6% 96·8% 428·7% 53·2% 217·6%
Kiribati 154·9% 323·3% 0·0% 6·4% 58·3%
Kuwait 51·6% 109·7% 37·6% 70·3% 0·0%
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Kyrgyzstan 117·6% 114·4% 139·3% 86·0% 98·0%
Laos 34·7% 53·7% 30·4% 91·8% 570·8%
Latvia 82·8% 89·5% 61·3% 132·4% 0·0%
Lebanon 100·1% 72·2% 574·1% 116·6% 422·6%
Lesotho 194·8% 175·0% 30·2% 33·8% 115·3%
Liberia 575·9% 0·0% 0·0% 20·0% 203·9%
Libya 80·2% 113·5% 0·2% 81·9% 8·3%
Lithuania 89·1% 93·8% 28·9% 126·3% 0·0%
Luxembourg 182·2% 108·5% 116·6% 59·1% 0·0%
Macedonia 106·8% 99·0% 0·0% 109·8% 63·2%
Madagascar 57·3% 146·3% 0·0% 80·4% 99·2%
Malawi 197·6% 197·2% 2043·1% 22·9% 104·1%
Malaysia 57·0% 78·6% 293·6% 138·4% 59·1%
Maldives 219·3% 123·2% 81·5% 56·8% 2·9%
Mali 121·0% 72·1% 1399·1% 97·2% 98·4%
Malta 130·7% 93·9% 70·4% 123·0% 0·0%
Marshall Islands 293·5% 149·1% 220·6% 27·2% 170·7%
Mauritania 64·0% 96·6% 128·7% 106·2% 87·6%
Mauritius 70·5% 75·4% 27·0% 161·6% 242·8%
Mexico 97·7% 77·9% 161·4% 142·9% 45·1%
Moldova 179·8% 93·3% 641·7% 94·2% 84·3%
Mongolia 78·7% 82·1% 37·5% 122·3% 752·2%
Montenegro 105·8% 85·0% 105·8% 129·1% 177·0%
Morocco 102·8% 56·4% 405·2% 157·4% 37·8%
Mozambique 119·0% 61·0% 93·7% 20·7% 196·6%
Myanmar 44·2% 73·7% 0·0% 110·7% 215·1%
Namibia 158·4% 88·2% 1495·1% 19·2% 600·0%
Nepal 95·9% 87·8% 732·5% 106·5% 81·7%
Netherlands 147·9% 114·1% 206·3% 27·3% 0·0%
New Zealand 145·5% 109·3% 231·1% 50·8% 0·0%
Nicaragua 157·9% 101·8% 306·9% 91·3% 101·0%
Niger 99·0% 168·1% 0·0% 124·4% 55·2%
Nigeria 65·6% 41·3% 53·1% 177·4% 127·5%
Norway 163·8% 106·1% 107·2% 72·6% 0·0%
Oman 46·3% 120·0% 76·9% 28·9% 0·0%
Pakistan 46·3% 64·2% 486·2% 135·6% 81·2%
Panama 116·5% 104·8% 163·9% 79·6% 758·5%
Papua New Guinea 73·5% 181·5% 488·4% 22·5% 121·6%
Paraguay 169·9% 77·2% 239·1% 133·7% 25·0%
Peru 87·6% 101·4% 276·0% 87·0% 48·7%
Philippines 80·9% 59·8% 614·9% 141·5% 50·7%
Poland 87·6% 100·0% 180·6% 91·6% 0·0%
Portugal 125·1% 91·4% 210·2% 113·5% 0·0%
Qatar 72·6% 112·2% 137·1% 37·8% 0·0%
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Romania 84·1% 116·9% 15·1% 64·2% 1012·3%
Russia 98·5% 72·3% 100·0% 178·1% 0·0%
Rwanda 149·8% 0·0% 3072·2% 51·5% 174·6%
Saint Lucia 113·2% 79·7% 37·3% 130·3% 441·0%
Saint Vincent 
and the Grenadines
150·1% 75·7% 95·9% 135·3% 284·7%
Samoa 125·8% 173·2% 0·0% 14·5% 90·4%
Sao Tome and Principe 133·8% 77·6% 874·5% 27·2% 320·8%
Saudi Arabia 63·0% 101·2% 197·0% 79·4% 0·0%
Senegal 85·6% 122·7% 0·0% 75·3% 120·5%
Serbia 167·5% 98·1% 13·4% 111·2% 23·9%
Seychelles 46·5% 131·3% 143·3% 9·2% 181·7%
Sierra Leone 218·9% 19·2% 1235·0% 112·7% 125·6%
Singapore 98·1% 54·3% 47·7% 311·5% 0·0%
Slovakia 103·5% 104·9% 0·0% 97·1% 0·0%
Slovenia 120·2% 99·2% 516·1% 52·7% 0·0%
Solomon Islands 94·2% 260·3% 0·0% 9·0% 99·6%
Somalia 87·6% 142·7% 164·2% 72·2% 107·2%
South Africa 146·2% 74·0% 1850·3% 19·2% 411·3%
South Korea 93·9% 74·7% 233·0% 168·7% 0·0%
South Sudan 61·1% 61·1% 0·0% 91·1% 190·8%
Spain 118·4% 95·1% 170·8% 107·6% 0·0%
Sri Lanka 58·9% 88·0% 45·8% 121·5% 229·0%
Sudan 143·6% 44·8% 80·1% 180·9% 19·7%
Suriname 66·5% 102·1% 592·7% 49·1% 716·5%
Swaziland 164·8% 115·5% 473·5% 26·6% 519·4%
Sweden 160·3% 110·3% 20·8% 71·9% 0·0%
Switzerland 199·2% 77·1% 452·0% 133·2% 0·0%
Syria 53·1% 67·6% 127·1% 165·3% 216·1%
Tajikistan 123·6% 63·6% 1024·3% 130·3% 56·5%
Tanzania 107·3% 58·5% 2069·5% 45·2% 213·9%
Thailand 65·2% 120·9% 337·4% 37·7% 195·2%
The Bahamas 107·4% 64·3% 899·4% 113·4% 0·0%
The Gambia 145·7% 202·4% 0·0% 31·1% 121·6%
Timor-Leste 33·0% 99·1% 0·0% 18·6% 634·8%
Togo 86·0% 140·6% 1091·4% 103·0% 51·9%
Tonga 92·3% 141·4% 32·8% 28·4% 217·7%
Trinidad and Tobago 77·9% 74·0% 242·1% 164·9% 0·0%
Tunisia 117·2% 92·4% 202·5% 109·3% 18·0%
Turkey 80·2% 115·7% 130·9% 61·3% 35·7%
Turkmenistan 35·6% 89·2% 331·7% 102·5% 238·5%
Uganda 293·2% 3·3% 8624·8% 36·7% 64·8%
Ukraine 120·5% 85·8% 45·9% 128·7% 53·6%
United Arab Emirates 63·4% 92·4% 273·9% 98·6% 0·0%
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development. Surrounding the modelled average, 
however, is a great deal of variation. Countries such as 
Afghanistan, Sudan, and Nigeria, spend more through 
OOP than expected. Conversely, countries such as 
Congo (Brazzaville), Algeria, South Africa, and France 
have a disproportionally smaller OOP share of total 
health spending.
Column 5 of table 2 reports the share of health 
spending that is from development partners, in this case 
measured relative to expected spending. As shown in 
figure 2F, development assistance for health as a share of 
total health spending actually increases with GDP per 
capita for the countries with the smallest GDP per capita; 
a number of countries, such as Niger, which has a very 
low GDP per capita, receive very little development 
assistance for health. Relative to the expected amount, 
countries such as Botswana, Romania, and Gabon 
finance a greater share of their health spending using 
development assistance funds than would otherwise be 
expected. On the other hand, countries such as Cameroon 
and Sudan finance their health spending with less 
development assistance funds than would be expected 
based on their GDP per capita.
Figure 4 shows total health spending and the share that 
is government health spending, both relative to the 
modelled amount, based solely on GDP per capita. 
Countries such as Algeria and Japan have greater than 
modelled health spending per capita and greater than 
modelled share of financing from government. Countries 
such as Uganda and the USA have greater than modelled 
health spending per capita, but less than modelled share 
of financing from government. Conversely, countries 
such as Ethiopia and Thailand, have less health spending 
per capita than modelled, but higher than modelled 
share of financing from government, and countries such 
as India, Indonesia, and Philippines have less health 
spending per capita than modelled and lower than 
modelled share of financing from government.
Trends in development assistance for health
Figures 5 and 6 highlight important trends related to 
development assistance for health, reported in 2015 US $. 
In 2016, total development assistance for health 
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UK 121·4% 109·0% 244·6% 46·9% 0·0%
USA 243·7% 63·8% 1211·9% 60·7% 0·0%
Uruguay 126·1% 103·3% 485·1% 55·2% 6·8%
Uzbekistan 102·4% 93·5% 165·1% 113·0% 41·6%
Vanuatu 90·0% 155·2% 0·0% 12·2% 208·0%
Venezuela 79·9% 43·4% 236·0% 217·4% 1·5%
Vietnam 121·9% 100·8% 494·6% 93·7% 44·3%
Yemen 100·2% 31·5% 161·1% 176·4% 83·5%
Zambia 93·7% 72·1% 0·0% 65·3% 351·9%
Table 2: Health spending relative to expected health spending, 2014
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Figure 4: Observed government and total health spending relative to modelled spending, 2014
The figure shows the total health spending relative to modelled spending, and the share of health spending that is 
from the government relative to the modelled share. The vertical and horizontal red lines indicate where the 
observed spending is equal to the modelled spending (100%). Although all countries and years of data were used 
for this analysis, the deviations reflects the 2014 model fit. Only countries with a population higher than 30 million 
and 2014 data are included as points to avoid too many markers. A version with all countries included a dots is 
included in the appendix (p 68). AFG=Afghanistan. ARG=Argentina. BGD=Bangladesh. BRA=Brazil. CAN=Canada. 
CHN=China. COD=Democratic Republic of the Congo. COL=Colombia. DEU=Germany. DZA=Algeria. EGY=Egypt. 
ESP=Spain. ETH=Ethiopia. FRA=France. GBR=UK. IDN=Indonesia. IND=India. IRN=Iran. IRQ=Iraq. ITA=Italy. 
JPN=Japan. KEN=Kenya. KOR=South Korea. MAR=Morocco. MEX=Mexico. MMR=Myanmar. NGA=Nigeria. 
PAK=Pakistan. PER=Peru. PHL=Philippines. POL=Poland. RUS=Russia. SAU=Saudi Arabia. SDN=Sudan. 
THA=Thailand. TUR=Turkey. TZA=Tanzania. UGA=Uganda. UKR=Ukraine. USA=USA. VEN=Venezuela. 
VNM=Vietnam. ZAF=South Africa.
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amounted to US$37·6 billion. Figure 5 shows the most 
recent growth rates in the disbursement of development 
assistance for health (figure 5A), and recent 
disbursements disaggregated by channel of assistance 
(figure 5B). In the 1990s, total development assistance for 
health grew at an annualised rate of 4·6%. During the 
first decade of the millennium, development assistance 
for health grew at an annualised rate of 11·3%, with 
especially large annualised growth for target areas 
associated with the Millennium Development Goals. 
Annualised growth between 2000 and 2009 was the 
highest for malaria, tuberculosis, and HIV/AIDS. 
Since 2010, total development assistance for health has 
grown at an annualised growth rate of 1·8%, with 
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Figure 5: Changes in development assistance for health disbursements, 1990–2016
Development assistance for health as annualised growth rates (A) and disaggregated by channel (B). (A) Growth rates are shown for 1990–99, 2000–09, and 2010–16. 
(B) Estimates are shown from 1990 to 2016, all in billions of 2015 US$. World Bank includes the International Development Association and the International Bank for 
Reconstruction and Development; and regional development banks include the Inter-American Development Bank, the African Development Bank, and the Asian 
Development Bank. NGOs=non-governmental organisations. Global Fund=The Global Fund to Fight AIDS, Tuberculosis and Malaria. Gavi=Gavi, the Vaccine Alliance. 
UNICEF=United Nations Children’s Fund. UNFPA=United Nations Population Fund. UNAIDS=Joint United Nations Programme on HIV/AIDS. PAHO=Pan American 
Health Organization. *Data for 2015 and 2016 are preliminary estimates based on budget data and estimation.
Articles
1998 www.thelancet.com   Vol 389   May 20, 2017
reductions in spending (–1·4%) for the largest health 
focus area, which is HIV/AIDS.
Between 1995 and 2014, $423·0 billion of development 
assistance for health was disbursed to low-income and 
middle-income countries (figure 6). 27·0% of develop-
ment assistance for health went to sub-Saharan Africa, 
whereas 7·9% flowed to Latin America and the 
Caribbean. Across health focus areas, 24·0% of 
development assistance for health focused on HIV/AIDS, 
while child and maternal health projects received 14·8% 
and 11·3% of funding, respectively. The majority of the 
resources were provided by national treasuries, including 
the USA at 34·0% and the UK at 10·9%, of total 
development assistance for health in 2016. Major shares 
Source Channel Health focus area GBD recipient region
Australia
$6·9b
Canada
$11·4b
France
$16·0b
Germany
$17·4b
UK
$31·8b
USA
$133·9b
Australia
$3·9b
HIV/AIDS
$101·4b
Southeast Asia, east Asia, 
and Oceania*
$27·9b
Central Europe, eastern 
Europe, and Central Asia
$10·6b
Latin America
and Caribbean
$33·4b
North Africa and 
Middle East
$12·3b
South Asia
$31·4b
Sub-Saharan Africa
$113·6b
Global initiatives
$59·3b
Unallocable
$133·6b
Malaria
$19·7b
Tuberculosis
$12·8b
Other infectious diseases
$16·2b
Newborn and child health
$62·4b
Maternal health
$47·7b
Non-communicable diseases
$5·4b
Health sector support
$49·8b
Other health focus areas
$90·5b
Unallocable
$16·2b
Canada
$4·8b
France
$7·0b
Germany
$8·4b
UK
$15·1b
USA
$75·3b
Other bilateral aid agencies
$36·2b
European Commission
$7·8b
UNICEF, UNFPA,
UNAIDS, and PAHO
$31·7b
WHO
$31·9b
Development banks
$50·3b
NGOs and foundations
$96·0b
The Bill & Melinda
Gates Foundation
$13·8b
Global fund
$29·9b
Gavi
$10·0b
Other governments
$87·7b
Private philanthropy
$45·7b
The Bill & Melinda
Gates Foundation
$19·6b
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$51·7b
Figure 6: Flow of developmental assistance for health for all funds dispersed, 1995–2014
The figures shows the flow of development assistance for health from sources, through intermediary channels, to health focus areas and the region where the development assistance was ultimately 
received. Data are cumulative developmental assistance for health from 1995 to the end of 2014 in billions of 2015 US$. Each column disaggregates the total developmental assistance for health 
disbursed from 1995 through to 2014, which was US$423·0 billion. Funding sources are shown on the left, channels in the middle left, health focus areas on the middle right, and Global Burden of 
Disease (GBD) recipient super-regions are on the right. Private philanthropy includes corporate donations among other private philanthropy. Other sources include debt repayments and funds whose 
sources are unallocable. NGOs and foundations include non-governmental organisations and US foundations. UN Agencies include the UN Children’s Fund, UN Population Fund, Joint UN Programme 
on HIV/AIDS, Pan American Health Organization, and WHO. Development banks include the World Bank International Development Association, the World Bank International Bank for Reconstruction 
and Development, the Inter-American Development Bank, the African Development Bank, and the Asian Development Bank. Other health focus areas correspond to developmental assistance for 
health for which we have project-level information but which is not identified as funding any of the health focus areas we tracked. Unallocable in terms of health focus area corresponds to 
developmental assistance for health for which we do not have project-level information and cannot parse across health focus areas. Latin America and the Caribbean includes Argentina, Chile, and 
Uruguay, which are now high-income countries when they were each middle-income countries. Southeast Asia, east Asia, and Oceania includes South Korea, which is also now a high-income country 
when it was a middle-income country. Unallocable in recipient region also corresponds to development assistance for health for which we do not have project-level information and thus, cannot parse 
across recipients. UNICEF=United Nations Children’s Fund. UNFPA=United Nations Population Fund. UNAIDS=Joint United Nations Programme on HIV/AIDS. PAHO=Pan American Health Organization. 
Global Fund=The Global Fund to Fight AIDS, Tuberculosis and Malaria. Gavi=Gavi, the Vaccine Alliance.
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of development assistance for health also flowed through 
multilateral development agencies, such as the World 
Bank and WHO, which disbursed 5·1% and 5·8%, 
respectively, and private-public partnerships, such as the 
Global Fund and Gavi, who disbursed 9·9% and 4·9%, 
respectively, in 2016.
Health spending by type of goods and service
Figure 7 shows that spending by type of goods and service 
was relatively constant across different levels of economic 
development. At the median GDP per capita ($8346), 
29·0% of total spending was on inpatient curative and 
rehabilitative care, 30·6% is on day and outpatient 
curative and rehabilitative care, and 23·5% is on medical 
goods, which include pharmaceuticals, in 2014 (figure 7A). 
These values drop marginally at the highest values of 
GDP per capita, where long-term care is more prominent.
Government spending by type of goods and service is 
very similar to total spending (figure 7B), although the 
government spends less on medical goods, in particular 
above the median GDP capita, and slightly more on 
immunisations and early disease detection at the very 
lowest levels of GDP per capita.
Discussion
This study identifies health spending trends and country-
specific deviations for 184 nations from 1995 to 2014. The 
findings show that, on average, economic development is 
associated with increases in health spending per person 
and decreases in the share of spending that is financed 
OOP. In addition to this, we show that development 
assistance for health also fits neatly into the framework 
outlined in the health financing transition—like OOP 
health spending, the share of health financing from 
development partners decreases precipitously with 
economic development.
Figure 3 highlights three distinct health financing 
stages that emerge along the spectrum of economic 
development. In the first stage, health financing is 
dominated by development assistance for health and 
OOP. In the second stage, development assistance for 
health subsides, and the primary sources of health-care 
financing are OOP and domestic government spending. 
Finally, the third stage includes countries with the highest 
GDP per capita, which tend to finance health care using 
government spending. While these stages are 
conceptually clear, and are neatly shown in figure 3, it is 
important to note the great deal of variation that exists 
around these trends. While the empirical evidence 
supporting the health financing transition is robust on 
average, many counter-examples exists. Some 
upper-middle-income countries such as Angola and 
Turkmenistan spent only $228 and $396, respectively, per 
capita on health in 2014. Similarly, some lower-middle-
income countries such as Sudan and Federated States of 
Micronesia rely heavily on OOP and development 
assistance for health. Despite the clear and intuitive 
trends articulated by the health financing transition, an 
important conclusion of this research is that country-
specific characteristics are central to health financing, 
and that time and economic development do not 
guarantee a transition towards adequate prepaid spending 
needed to support universal health coverage. The trends 
shown here are encouraging, although substantive 
deviation from the trends are in some cases worrisome.
At the nexus of economic development and health 
financing are concerns related to what some have called the 
missing middle. This missing middle concept, which has 
been debated, asserts that in the process of transitioning 
from low-income to middle-income status, countries receive 
less development assistance for health although they are not 
yet able to domestically raise sufficient government 
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Figure 7: Composition of health spending by type of goods and services, 2014
The modelled proportion of total (A) and government (B) health spending across gross domestic product per capita by types of goods and services. Other health 
spending includes all other health spending that is not otherwise classified in this taxonomy. Spending on education and counselling programs, epidemiological 
surveillance, and disaster preparedness was excluded.
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resources to replace the lost external resources.43,44 
Identifying, understanding, and managing this potential is 
of crucial importance because more than 70% of the world’s 
poor live in middle-income-countries.45 A result of a 
premature transition from development assistance for 
health would be a reduction in prepaid, pooled resources, 
and an increase in OOP financing. Our estimates provide 
some evidence of this occurrence, because lower-middle-
income countries finance more of their health spending 
OOP than any other income group.
Trends in development assistance for health 
disbursement draw even more attention to the missing 
middle concern, because the growth rates of development 
assistance for health disbursement have slowed 
substantially since 2010, causing some donors to re-
evaluate their own development assistance for health 
allocation policies.46 Along with this, some key health 
focus areas have recently experienced tepid growth, and 
funds for HIV/AIDS, which for the past 15 years has 
been the largest development assistance health focus 
area, have contracted since 2010. In some cases this 
comes after major gains have been made.47–49 For many 
low-income countries and some missing middle-income 
countries, these trends could have crucial impacts on the 
provision of essential health services, unless the trends 
reverse or domestic funds are identified.
Development assistance for health disbursements 
grew substantially between 2000 and 2010. Although this 
period, referred to as the so-called golden age of 
development assistance for health growth, saw annual 
disbursement more than triple, how these disbursements 
affected total health spending in low-income and middle-
income countries remains unclear.50 In some cases, this 
disbursement might prop up domestic spending and 
hide the true amount of spending that is being financed 
domestically. In other cases, development assistance 
could have crowded out or replaced government 
spending that would have otherwise exsisted.51,52 Because 
development assistance for health is not always 
predicable and sustainable, ongoing maturation of 
domestic prepaid financing is important.
While a shift from a reliance on development assistance 
for health can be externally imposed upon some countries, 
the shift from a reliance on OOP must be driven by internal, 
institutional forces. Political efforts and health-system 
reform have encouraged movement away from OOP 
financing in countries such as Mexico and Thailand. While 
these countries reduced the share of health spending that 
was OOP as middle-income countries, this transition 
occurs, on average, later in the process of economic 
development. Our estimates (figures 2 and 3) show that 
while the share of health spending from OOP peaks at GDP 
per capita of $2456, it remains a major source of spending 
for many countries beyond this point. The modelled trends 
do not show an accelerated decline in spending from OOP 
till above GDP per capita of $20 000. This threshold is 
crucial because OOP financing has been linked to less 
access to prescribed medicines, less access to care, more 
adverse health outcomes, and impoverishment.15,16,20,53
In addition to tracking total health spending and health 
spending by source, this study also highlights how the type 
of health-care services purchased is relatively stable across 
the spectrum of economic development. While these 
trends are quite stable in relative terms, the exponential 
growth of total health spending means that in absolute 
terms, much more is being spent on each type of goods 
and service in high-income countries than in low-income 
countries. In relative terms, trends do show that countries 
with the lower GDP per capita spent more proportionally 
on medical goods, which includes pharmaceuticals, and 
their governments spend relatively more on immunisation 
and early disease detection. Most clear is that spending on 
long-term care is minimal in low-income countries, 
whereas it grows to 20% in high-income countries. In 
many low-income countries, long-term care remains 
informal and relies on volunteers and community care.54
Long-term care is only one type of service associated 
with the epidemiological transition and the shift from a 
health burden dominated by infectious and childhood 
diseases to a health burden dominated non-
communicable, chronic conditions. While many middle-
income countries are dealing with this double burden 
simultaneously, planning within low-income countries 
should revolve around ensuring progress along this 
epidemiological transition, while also anticipating the 
additional financing challenges associated with this 
transition.55 In many cases, these challenges include 
caring for an older population with chronic conditions 
and in many cases complex comorbidities. Recent US 
research shows that in the USA, 70% of personal health 
spending is on non-communicable diseases.56 This 
research shows that a dramatic shift in how resources are 
allocated across types of goods and services is not the 
norm, although, in most cases, considerably more 
resources are used to care for these populations.
Sufficient supply of prepaid, pooled health resources, 
such as government spending, is crucial in the pursuit of 
universal health coverage.57 If, like the health financing 
transition describes, this health spending is encouraged 
by economic development, then economic growth is a 
catalyst for progress towards universal health coverage. 
This research affirms these trends on average, but also 
highlights substantial deviations from these trends. The 
reality is that many factors determine a country’s health 
spending level, including factors related to the 
population’s age pattern and health burden, the supply 
and demand of health care, prices, adaptation of new 
medical technology, and many health-system 
characteristics, including health-system efficiency.58–60 
These same factors might also be integral in transitioning 
from reliance on OOP financing to prepaid financing. 
While national income can constrain health spending, 
these shifts in financing might be more connected to 
comprehensive socioeconomic development. Moreover, 
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health-system reform is generally a political process that 
is affected, but not purely determined, by any one of these 
additional factors. Ongoing assessment of these factors is 
crucial for informed pursuit of universal health coverage.
This research has several limitations that revolve 
around the data availability and data quality. The WHO 
Global Health Observatory is the only curator of some of 
the estimates used in this study: government, prepaid 
private, and OOP health spending estimates that span 
worldwide. These data are intended to be comparable, 
although estimates across time and release versions can 
vary substantially. The estimates of private spending, 
including OOP and prepaid private spending, are 
particularly concerning because the underlying input 
data are sparse and vary in quality. In addition, these data 
are reported as spending agent, rather than as the source 
of the financing. Spending estimates fluctuate drastically 
across time for many countries and might hint at 
inconsistency in tracking across time rather than dramatic 
spending shifts. Moving forward, more effort is needed to 
evaluate and validate these health financing data.
An additional data limitation is that NHA reports are 
sparse and contain gaps.61 These issues prevent analysis 
at a more granular level. Although the framework for 
completing NHAs is standardised, the actual methods 
used to complete an NHA report vary across countries 
and time. This is particularly the case in many low-
income and middle-income settings, where generation 
of an NHA relies less on routinely collected data and 
more heavily on approximation. Like the data from the 
WHO Global Health Observatory, these data are 
tremendously powerful, although scarcity and quality 
suggest additional assessment, validation, and correcting 
of any discovered biases is necessary.
Furthermore, like the spending by source data from the 
WHO and the spending by type data from the NHAs, 
IHME’s development assistance for health data relies on 
estimation and approximation to fill in incomplete data. In 
particular, estimates of development assistance for health 
rely on modelling of disbursement data when only 
commitment data are available and keyword searches of 
project level data when health focus areas are not clearly 
identified. In addition, these data capture development 
assistance for health from the bilateral aid agencies from 
high-income countries only, missing any so-called South–
South cooperation in the health sector. In addition to these, 
some development assistance for health is not allocable to 
a specific country because the development agency does 
not report project level information. When development 
assistance for health can be allocated to a specific country, 
it might remain unclear if all the development assistance 
for health was actually disbursed within that country. 
Because country-specific development assistance for 
health estimates are used to estimate domestic government 
and private health spending, development assistance for 
health measurement error might cause measurement 
error in these other metrics. Measurement error and 
misalignment of government spending and development 
assistance for health even lead to domestic government 
spending estimates for some countries falling below zero, 
after development assistance for health provided to the 
government is removed. More transparency and complete 
reporting of development assistance for health, including 
precise information about where resources are spent and 
who was the primary recipient, would lead to improved 
development assistance for health tracking.
Two final data limitations are that many of the estimates 
reported in this study are reported using PPP $ and none of 
the data sources used for this study provide subnational 
spending estimates. The empirical basis for some 
purchasing power parity adjustments is weak, despite 
ongoing efforts to improve them.62 In addition, the absence 
of subnational data prevented the examination of within-
country heterogeneity in health financing. GDP per capita 
does not capture income equality, and health spending 
within many countries varies substantially, and many cases 
substantial health spending inequalities exist.63,64 Spending 
levels and the share prepaid can vary greatly, particularly in 
countries with a small government share of health 
spending. Many key dimensions, such as income, wealth, 
race, geography, age, sex, and economic status, are glossed 
over when estimates are reported in national, per capita 
terms only. Because this study focuses on national spending, 
it abstracts from these critical variations. Future analyses 
should aim to assess the health financing transition within 
countries, while globally more efforts need to be made to 
collect subnational health financing data.
In addition to these data concerns, it is also important to 
recognise that this research has not tracked health 
spending in relation to health outcomes. More spending 
on health does not guarantee better health outcomes. A 
recent report from the OECD have shown that a substantial 
share of health spending in high-income countries is 
wasted.65 Coupled with efforts to ensure adequate prepaid 
resources for health must be efforts to ensure that health 
services are provided efficiently and equitably.
In conclusion, the availability of prepaid resources for 
health, such as government spending, is one of many 
determinants of access to health care, and can lead to 
population health gains. Economic development is 
associated with an increase in spending and specifically 
an increase in prepaid resources. This is at the core of the 
pursuit for universal health coverage. This research also 
points to countries that deviate from the trends, spending 
more or less than expected, based on their level of 
economic development. This information is valuable to 
planners assessing funding gaps and financing 
opportunities, and can be used to provide insight into 
what future health financing challenges are likely. 
Tracking changes in health financing patterns across 
time and benchmarking against global trends is vital to 
addressing missed opportunities, ensuring access to 
medicines and high quality services, and the pursuit of 
universal health coverage.
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